Orchestra BioMed Holdings, Inc.
Wealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.
Hochman David P (See Remarks) purchased 10,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.79 on 2026-09-03.
Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OBIO (Orchestra BioMed Holdings, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent OBIO coverage spans financial news, insider activity and market movers.
In the last 30 days, OBIO insiders filed 3 SEC Form 4 transactions — 2 purchases ($59K) and 1 sale ($74K). The most active reporter was Sherman Darren, See Remarks, with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade may sustain price rally.
Small insider purchase, likely limited immediate price impact.
Regulatory breakthrough and trial data create upside potential.
Breakthrough designation plus additional capital can accelerate development and improve investor confidence in regulatory path and trial execution.
Routine shareholder-meeting outcomes; limited direct implications for near-term fundamentals beyond governance/comp-plan housekeeping.
AlphAI scores every news story that mentions OBIO with an AI model for sentiment and relevance, and aggregates insider trades from Orchestra BioMed Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.
2 min readHochman David P (See Remarks) purchased 10,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.79 on 2026-09-03.
1 min readSeveral biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
3 min readAmylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
4 min readOrchestra BioMed Holdings, Inc. (OBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001814114 0001814114 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
3 min readHochman David P (See Remarks) purchased 5,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.83 on 2026-06-01.
2 min readRTW funds have exercised 1,250,032 pre-funded warrants of Orchestra BioMed (NASDAQ: OBIO) at $0.0001 per share on a cashless basis. This transaction resulted in the issuance of 1,250,000 shares to RTW, with 32 shares withheld to cover the exercise price. Following the exercise, the RTW funds indirectly hold 9,556,095 shares of common stock and 2,386,331 pre-funded warrants, while adhering to a beneficial ownership cap of 19.99%.
2 min readRTW Investments and affiliated funds have increased their beneficial ownership in Orchestra BioMed Holdings to 19.2% after exercising pre-funded warrants. On April 27, 2026, RTW funds exercised pre-funded warrants for 1,250,032 shares on a cashless basis, resulting in 1,250,000 new common shares for Orchestra BioMed. This transaction, combined with additional exercisable warrants, means RTW Investments and Dr. Roderick Wong beneficially own 11,942,394 shares.
2 min readNEW HOPE, Pa., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO ) ( "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, ...
3 min readNEW HOPE, Pa., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO ) ( "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, ...
2 min read